longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Ord Minnett Keeps Their Buy Rating on Impedimed Limited (IPDQF)

Tip Ranks
May 12, 2026 at 01:06 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ord Minnett analyst Tom Godfrey has reaffirmed a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.02. The analyst focuses on the Healthcare sector and has an average return of 45.7% with a 51.72% success rate on his stock recommendations. The current consensus on Impedimed Limited is a Strong Buy, with an average price target of A$0.03.

Ord Minnett analyst Tom Godfrey maintained a Buy rating on Impedimed Limited today and set a price target of A$0.02.

Claim 55% Off TipRanks

  • Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
  • Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Godfrey covers the Healthcare sector, focusing on stocks such as Impedimed Limited, Sigma Healthcare Ltd, and Regis Healthcare Ltd.. According to TipRanks, Godfrey has an average return of 45.7% and a 51.72% success rate on recommended stocks.

Currently, the analyst consensus on Impedimed Limited is a Strong Buy with an average price target of A$0.03.

Login to unlock197characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 10, 2026 at 05:40 AMWorld’s largest contract chipmaker TSMC sees August revenue surge over 53% to record high

Related Stocks

Impedimed Limited

Impedimed Limited

AUIPD

Sigma Healthcare Ltd

Sigma Healthcare Ltd

AUSIG

Regis Healthcare Ltd.

Regis Healthcare Ltd.

AUREG

LongbridgeAI